Manch-based Boston Therapeutics closes $5.3M placement of common stock, warrants
Proceeds of the offering will be used to fund additional clinical trials for PAZ320, a non-systemic chewable drug designed to reduce the elevation of postprandial glucose or post-meal blood sugar for treatment of patients with Type 2 diabetes, and for general corporate purposes.
LATEST NEW HAMPSHIRE ANGLE
Ruth Graham: Whatever your theology, your denomination, your interests, and your appetite for cursing, there’s a Christian podcast for you.
Joe McQuaid's Publisher's Notes: President's offspring always off limits? My grandfather would beg to differ